Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Conduit Pharmaceuticals Inc. (CDTTW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: CDTTW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -64.29% | Avg. Invested days 6 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 |
52 Weeks Range 0.01 - 0.05 | Updated Date 05/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -168.26% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 552357 |
Shares Outstanding - | Shares Floating 552357 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Conduit Pharmaceuticals Inc.
Company Overview
History and Background
Conduit Pharmaceuticals Inc. was formed in 2023 through a business combination with Murphy Canyon Acquisition Corp., a special purpose acquisition company (SPAC). The company's strategy is to in-license clinical-stage drug candidates.
Core Business Areas
- Clinical Development: Focuses on developing in-licensed pharmaceutical assets through clinical trials, aiming for regulatory approval and commercialization.
Leadership and Structure
Dr. Allan Shaw is the CEO. The company operates with a management team overseeing clinical development and business operations. Their structure is a typical pharmaceutical model with departments covering clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- AZD1656 (exenatide extended release): A once-weekly extended-release formulation of exenatide designed for the treatment of type 2 diabetes, which they have in-licensed. Competitors include Novo Nordisk (NVO) with Ozempic and Eli Lilly (LLY) with Trulicity. Data for market share or revenue specific to Conduit is unavailable as the product is still in development. Current market is dominated by Novo Nordisk and Eli Lilly.
- Remogliflozin Etabonate: A selective inhibitor of the sodium glucose co-transporter 2 for the treatment of type 2 diabetes, which they have in-licensed. Competitors include Johnson & Johnson (JNJ) with Invokana and AstraZeneca (AZN) with Farxiga. Data for market share or revenue specific to Conduit is unavailable as the product is still in development. Market is dominated by AstraZeneca and Johnson & Johnson.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. It is currently experiencing high growth with a focus on innovative therapies and personalized medicine.
Positioning
Conduit Pharmaceuticals is positioning itself as a company focused on developing and commercializing already de-risked, clinical-stage drug candidates. Their advantage lies in in-licensing potentially promising assets, which can reduce the initial R&D burden compared to developing drugs from scratch.
Total Addressable Market (TAM)
The global diabetes market is estimated to be valued at hundreds of billions of dollars. Conduit is positioned to capture a share of this market through its diabetes treatment candidates. The exact TAM for their specific products will depend on their effectiveness, market acceptance, and competitive landscape.
Upturn SWOT Analysis
Strengths
- In-licensing model potentially reduces initial R&D costs
- Experienced leadership team in drug development
- Focus on clinical-stage assets offers reduced risk compared to early-stage research
Weaknesses
- Reliance on in-licensed assets makes them dependent on third-party innovation
- No currently marketed products generate revenue
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Further in-licensing of promising clinical-stage assets
- Partnerships with larger pharmaceutical companies for development and commercialization
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies with greater resources
- Patent expirations or challenges
Competitors and Market Share
Key Competitors
- NVO
- LLY
- AZN
- JNJ
Competitive Landscape
Conduit Pharmaceuticals faces intense competition from established pharmaceutical giants with significantly greater resources and established market presence. Their success hinges on the successful development and commercialization of their in-licensed assets.
Growth Trajectory and Initiatives
Historical Growth: Not Applicable (Recent Company Formation)
Future Projections: Future growth depends heavily on clinical trial success and regulatory approvals of its lead assets. Analyst estimates are contingent on these milestones.
Recent Initiatives: Focusing on the progress of clinical trials for its lead compounds and seeking potential partnerships for later-stage development and commercialization.
Summary
Conduit Pharmaceuticals is a newly formed company leveraging an in-licensing model to develop clinical-stage diabetes treatments. While this approach potentially reduces initial R&D costs, the company faces significant risks related to clinical trial success and competition from larger pharmaceutical players. Securing partnerships and navigating regulatory hurdles will be crucial for its future growth. The current lack of revenue is a considerable weakeness.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Industry Reports
- Analyst Reports
- Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It does not constitute financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Conduit Pharmaceuticals Inc.
Exchange NASDAQ | Headquaters Naples, FL, United States | ||
IPO Launch date 2023-09-25 | Founder, CEO & Director Dr. Andrew Regan | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.conduitpharma.com |
Full time employees 6 | Website https://www.conduitpharma.com | ||
Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was founded in 2019 and is based in Naples, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.